{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:28:44Z","timestamp":1789921724374,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.vaccine.2017.05.057","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T12:30:20Z","timestamp":1496406620000},"page":"3718-3725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model"],"prefix":"10.1016","volume":"35","author":[{"given":"Minna M.","family":"Hankaniemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli H.","family":"Laitinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirbabak","family":"Sioofy-Khojine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha A.E.","family":"M\u00e4\u00e4tt\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r G.","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varpu","family":"Marjom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Hy\u00f6ty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Flodstr\u00f6m-Tullberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesa P.","family":"Hyt\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2017.05.057_b0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1128\/CMR.00077-12","article-title":"Human rhinoviruses","volume":"26","author":"Jacobs","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.05.057_b0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.meegid.2012.10.016","article-title":"Picornavirus and enterovirus diversity with associated human diseases","volume":"14","author":"Tapparel","year":"2013","journal-title":"Infect Genet Evol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.05.057_b0015","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1128\/JVI.71.12.9743-9752.1997","article-title":"Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus","volume":"71","author":"Curry","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.057_b0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jcv.2016.06.007","article-title":"Predominance of enterovirus B and echovirus 30 as cause of viral meningitis in a UK population","volume":"81","author":"Holmes","year":"2016","journal-title":"J Clin Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.05.057_b0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jmv.23359","article-title":"Molecular characteristics of human coxsackievirus B1 infection in Korea, 2008\u20132009","volume":"85","author":"Kim","year":"2013","journal-title":"J Med Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.05.057_b0030","doi-asserted-by":"crossref","first-page":"e85023","DOI":"10.1371\/journal.pone.0085023","article-title":"Novel and predominant pathogen responsible for the enterovirus-associated encephalitis in eastern China","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vaccine.2017.05.057_b0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.ANC.0000296631.80926.8d","article-title":"A case report of a premature infant with coxsackie B1 meningitis","volume":"7","author":"Callen","year":"2007","journal-title":"Adv Neonatal Care"},{"key":"10.1016\/j.vaccine.2017.05.057_b0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcv.2016.07.003","article-title":"Pulmonary hemorrhage due to Coxsackievirus B infection-A call to raise suspicion of this important complication as an end-stage of enterovirus sepsis in preterm twin neonates","volume":"82","author":"Orbach","year":"2016","journal-title":"J Clin Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.05.057_b0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1089\/vim.2004.17.358","article-title":"Coxsackievirus-induced pancreatitis","volume":"17","author":"Huber","year":"2004","journal-title":"Viral Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2017.05.057_b0050","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1086\/605089","article-title":"Outbreak of life-threatening Coxsackievirus B1 myocarditis in neonates","volume":"49","author":"Verma","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2017.05.057_b0055","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1086\/605090","article-title":"Increased activity of Coxsackievirus B1 strains associated with severe disease among young infants in the United States, 2007\u20132008","volume":"49","author":"Wikswo","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2017.05.057_b0060","first-page":"553","article-title":"Increased detections and severe neonatal disease associated with coxsackievirus B1 infection\u2013United States, 2007","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2017.05.057_b0065","doi-asserted-by":"crossref","first-page":"e0129272","DOI":"10.1371\/journal.pone.0129272","article-title":"Transmission and demographic dynamics of Coxsackievirus B1","volume":"10","author":"Chu","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2017.05.057_b0070","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3349\/ymj.2014.55.6.1562","article-title":"Coxsackievirus B infection is highly related with missed abortion in Korea","volume":"55","author":"Hwang","year":"2014","journal-title":"Yonsei Med J"},{"issue":"6","key":"10.1016\/j.vaccine.2017.05.057_b0075","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s10156-013-0629-2","article-title":"Neonatal hemophagocytic lymphohistiocytosis associated with a vertical transmission of coxsackievirus B1","volume":"19","author":"Fukazawa","year":"2013","journal-title":"J Infect Chemother"},{"issue":"8","key":"10.1016\/j.vaccine.2017.05.057_b0080","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1586\/14760584.2014.933078","article-title":"Developing a vaccine for Type 1 diabetes through targeting enteroviral infections","volume":"13","author":"Hyoty","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2017.05.057_b0085","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/db13-0619","article-title":"Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes","volume":"63","author":"Laitinen","year":"2014","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.vaccine.2017.05.057_b0090","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2337\/db13-0620","article-title":"Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes","volume":"63","author":"Oikarinen","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2017.05.057_b0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijid.2015.04.018","article-title":"Post-poliomyelitis syndrome as a possible viral disease","volume":"35","author":"Baj","year":"2015","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2017.05.057_b0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/rmv.1883","article-title":"Enteroviral proteases: structure, host interactions and pathogenicity","volume":"26","author":"Laitinen","year":"2016","journal-title":"Rev Med Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.05.057_b0105","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tem.2014.08.002","article-title":"Enteroviruses as causative agents in type 1 diabetes: loose ends or lost cause?","volume":"25","author":"Morgan","year":"2014","journal-title":"Trends Endocrinol Metab"},{"issue":"26","key":"10.1016\/j.vaccine.2017.05.057_b0110","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1016\/j.vaccine.2016.02.077","article-title":"Status of research and development of vaccines for enterovirus 71","volume":"34","author":"Reed","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2017.05.057_b0115","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.vaccine.2017.05.057_b0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2014.01.013","article-title":"Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice","volume":"104","author":"Koho","year":"2014","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.vaccine.2017.05.057_b0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni771","article-title":"Target cell defense prevents the development of diabetes after viral infection","volume":"3","author":"Flodstrom","year":"2002","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.05.057_b0130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s00125-014-3436-0","article-title":"A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models","volume":"58","author":"Larsson","year":"2015","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.vaccine.2017.05.057_b0135","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/jmv.23903","article-title":"Coxsackievirus B1 reveals strain specific differences in plasmacytoid dendritic cell mediated immunogenicity","volume":"86","author":"Hamalainen","year":"2014","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.05.057_b0140","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00125-013-2834-z","article-title":"Previous maternal infection protects offspring from enterovirus infection and prevents experimental diabetes development in mice","volume":"56","author":"Larsson","year":"2013","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.vaccine.2017.05.057_b0145","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/erv.09.19","article-title":"Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines","volume":"8","author":"Barrett","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.05.057_b0150","unstructured":"WHO Expert Committee On Biological Standardization http:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/cells\/WHO_TRS_878_A1Animalcells.pdf?ua=1. World Health Organ Tech Rep Ser 1998; 878: i,vi, 1-101."},{"issue":"3","key":"10.1016\/j.vaccine.2017.05.057_b0155","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nprot.2008.12","article-title":"Purification of human plasma fibronectin using immobilized gelatin and Arg affinity chromatography","volume":"3","author":"Speziale","year":"2008","journal-title":"Nat Protoc"},{"issue":"20","key":"10.1016\/j.vaccine.2017.05.057_b0160","doi-asserted-by":"crossref","first-page":"11955","DOI":"10.1128\/JVI.01809-14","article-title":"Effect of formaldehyde inactivation on poliovirus","volume":"88","author":"Wilton","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.057_b0165","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu Rev Microbiol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.05.057_b0170","doi-asserted-by":"crossref","first-page":"e83374","DOI":"10.1371\/journal.pone.0083374","article-title":"Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals","volume":"8","author":"Thomassen","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vaccine.2017.05.057_b0175","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1586\/14760584.2016.1138862","article-title":"EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD)","volume":"15","author":"Mao","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2017.05.057_b0180","doi-asserted-by":"crossref","first-page":"e34834","DOI":"10.1371\/journal.pone.0034834","article-title":"Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates","volume":"7","author":"Chou","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.05.057_b0185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2016.02.008","article-title":"Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles","volume":"129","author":"Liu","year":"2016","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.vaccine.2017.05.057_b0190","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1128\/JVI.01464-15","article-title":"Engineering enhanced vaccine cell lines to eradicate vaccine-preventable diseases: the polio end game","volume":"90","author":"van der Sanden","year":"2015","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2017.05.057_b0195","doi-asserted-by":"crossref","first-page":"e20005","DOI":"10.1371\/journal.pone.0020005","article-title":"Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.05.057_b0200","unstructured":"Sanofi Pasteur. Poliovirus Vaccine Inactivated IPOL. http:\/\/products.sanofi.com.au\/vaccines\/IPOL_NZ_PI.pdf; 2008."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17307053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17307053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T09:00:22Z","timestamp":1602234022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17307053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":40,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0264410X17307053"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}